brentuximab,doxorubicin hydrochloride,dacarbazine,filgrastim,pegfilgrastim,nivolumab,vinblastine sulfate
seagen,amgen,bms
['hodgkin', 'lymphoma', 'nivolumab', 'nivo', 's1826']
#asco23 - lba4 presenter by dr. alex herrera #results of the swog s1826 study. in high risk advanced #classical #hodgkin #lymphoma are we transitioning to a new standard of care ? nivolumab-avd 1-year pfs of 94% vs 86% in a-avd. excited results 
leader,doctor,scientist,artist,Associate Director. Top doctors. Medical schools educator,Life Coach and mentor, Transplanter